---
title: "Tinlarebant (LBS-008) in Stargardt disease type 1: Clinical evidence"
description: "Formulary evidence on Tinlarebant (LBS-008) in Stargardt disease type 1: Clinical evidence. Covers DRAGON, DRAGON II, LBS-008-CT02, and LBS-008-CT09. 62 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tinlarebant (LBS-008) in Stargardt disease type 1: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 DRAGON

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Primary study objective

> “assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1”

Source: [Stanford Health Care](https://stanfordhealthcare.org/trials/p/NCT05244304.html)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Original UK protocol: ethics opinion

| Field | Quoted record |
| --- | --- |
| Ethics opinion date | “25 Nov 2021” |
| Ethics committee | “Wales REC 5” |

Source: [UK Health Research Authority (2021)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-study-of-tinlarebant-as-treatment-for-adolescent-stargardt-disease/)

<a id="topic-3.1.1.2-2"></a>

###### Completion of the final study visit

> “In September 2025, we completed the last subject visit in the Phase 3 DRAGON trial.”

Source: [Belite Bio Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### DRAGON pivotal phase 3 trial: trial design

> “Completed, 24-month, 104 subjects, aged 12 to 20 years old, randomized (2:1, active: placebo), double-masked, placebo-controlled, global, multi-center, pivotal Phase 3 trial”

Source: [Belite Bio first quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-first-quarter-2026-financial/)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### DRAGON pivotal phase 3 trial: enrollment criteria

> “All enrolled patients had an aggregate atrophic lesion size of 0.05–7.62 mm² and best-corrected visual acuity of ≥ 20/200.”

Source: [Edwards et al. (2026)](https://onlinelibrary.wiley.com/doi/10.1111/ceo.70050)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### DRAGON pivotal phase 3 trial: treatment groups

| “Tinlarebant” | “placebo” |
| ------------: | --------: |
|        “n=69” |    “n=35” |

Source: [Belite Bio DRAGON topline results announcement (2025)](https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite/)

Additional sources: [UK Health Research Authority (2021)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-study-of-tinlarebant-as-treatment-for-adolescent-stargardt-disease/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using DDAF Lesion Growth as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint and reported regulatory agreement

> “Primary Endpoint: Reduction in DDAF lesion growth rate, assessed by FAF imaging (as agreed with the FDA)”

Source: [Bernstein et al. (2026)](https://investors.belitebio.com/static-files/55440621-72d4-44c5-9719-7f53a28e8591)

<a id="topic-3.1.1.6.1-2"></a>

###### Planned patient-reported assessments

> “quality of life questionnaires.”

Source: [UK Health Research Authority (2021)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-study-of-tinlarebant-as-treatment-for-adolescent-stargardt-disease/)

<a id="topic-3.1.1.6.1-3"></a>

###### Visual-acuity endpoint: natural-history rate of change

> “Overall, BCVA declined at a rate of 0.011 logMAR per year (−0.55 letters/y)”

Source: [Kong et al. (2018)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2684573)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Original UK protocol: planned enrollment

| Population | Planned participants |
| --- | --- |
| Global | “60” |
| United Kingdom | “6” |

Source: [UK Health Research Authority (2021)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-study-of-tinlarebant-as-treatment-for-adolescent-stargardt-disease/)

<a id="topic-3.1.1.7.1-2"></a>

###### DRAGON: randomized and analyzed populations

| Population | Quoted record |
| --- | --- |
| Safety set | “N = 104” |
| Modified full analysis set | “N = 96” |

Source: [Belite Bio company presentation (2026)](https://investors.belitebio.com/static-files/837a64fe-a778-4209-9239-313d77a3aa0f)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Modified full analysis set: baseline and post-baseline requirements

> “mFAS subjects must have a defined DDAF lesion meeting the eligibility criteria at baseline and have at least one post baseline assessment.”

Source: [Belite Bio company presentation (2026)](https://investors.belitebio.com/static-files/837a64fe-a778-4209-9239-313d77a3aa0f)

<a id="topic-3.1.1.7.2-2"></a>

###### Primary statistical model

> “an unstructured covariance matrix under the Mixed Model for Repeated Measures (MMRM).”

Source: [Belite Bio DRAGON topline results announcement (2025)](https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite/)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### DRAGON pivotal phase 3 trial: treatment-related discontinuations

> “four treatment-related discontinuations”

Source: [Belite Bio DRAGON topline results announcement (2025)](https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite/)

<a id="topic-3.1.1.8.1-2"></a>

###### Interim participant disposition

> “By the time of the interim analysis, 87 (84%) of subjects had completed Month 16.”

Source: [Edwards et al. (2026)](https://onlinelibrary.wiley.com/doi/10.1111/ceo.70050)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

Additional sources: [Sui et al. (2025)](https://iovs.arvojournals.org/article.aspx?articleid=2805908)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### DRAGON: primary-endpoint results

| Endpoint, population, treatment, or analysis | Source quotation |
| -------------------------------------------- | ---------------- |
| “DDAF”                                       | “Study Eye”      |
| “mFAS”                                       | “N = 96”         |
| “Tinlarebant 5 mg”                           | “0.38 mm²/year”  |
| “Placebo”                                    | “0.59 mm²/year”  |
| “treatment effect size”                      | “35.7%”          |
| “unstructured covariance matrix”             | “P = 0.0033”     |

Source: [Belite Bio company presentation (2026)](https://investors.belitebio.com/static-files/837a64fe-a778-4209-9239-313d77a3aa0f)

<a id="topic-3.1.1.8.3-2"></a>

###### DRAGON pivotal phase 3 trial: visual acuity

> “the overall change in visual acuity was minimal over the period of 24 months in both study groups”

Source: [Belite Bio DRAGON topline results announcement (2025)](https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite/)

<a id="topic-3.1.1.8.3-3"></a>

###### DRAGON quantitative autofluorescence secondary endpoint: tinlarebant

> “qAF values remained stable to slightly decreased from baseline (approximately 2%)”

Source: [Belite Bio ASRS oral presentation announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-oral-presentation-asrs-annual-meeting)

<a id="topic-3.1.1.8.3-4"></a>

###### DRAGON quantitative autofluorescence secondary endpoint: placebo

> “placebo-treated subjects showed an approximate 20% increase in qAF from baseline.”

Source: [Belite Bio ASRS oral presentation announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-oral-presentation-asrs-annual-meeting)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### DRAGON pivotal phase 3 trial: adverse events

> “Xanthopsia and delayed dark adaptation were the most common drug related ocular adverse events.”
> “Headaches were the most commonly reported treatment-related non-ocular adverse events.”

Source: [Belite Bio Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm)

<a id="topic-3.1.1.8.5-2"></a>

###### DRAGON pivotal phase 3 trial: serious non-ocular treatment-emergent adverse events

> “6 serious non-ocular TEAEs”
> “4 assessed as unrelated and 2 assessed as unlikely related to the study treatment”

Source: [Bernstein et al. (2026)](https://investors.belitebio.com/static-files/55440621-72d4-44c5-9719-7f53a28e8591)

<a id="topic-3.1.1.8.5-3"></a>

###### Non-ocular adverse events: safety population

| Category | Tinlarebant 5 mg, 69 participants | Placebo, 35 participants |
| --- | --- | --- |
| Any non-ocular TEAE | “59 (85.5%)” | “27 (77.1%)” |
| Serious non-ocular TEAE | “2 (2.9%)” | “4 (11.4%)” |
| Drug-related non-ocular TEAE | “14 (20.3%)” | “4 (11.4%)” |
| Non-ocular TEAE resulting in study-drug discontinuation | “0 (0.0%)” | “0 (0.0%)” |

Source: [Belite Bio company presentation (2026)](https://investors.belitebio.com/static-files/837a64fe-a778-4209-9239-313d77a3aa0f)

<a id="topic-3.1.1.8.5-4"></a>

###### Ocular adverse events: safety population

| Category | Tinlarebant 5 mg, 69 participants | Placebo, 35 participants |
| --- | --- | --- |
| Any ocular TEAE | “53 (76.8%)” | “8 (22.9%)” |
| Drug-related ocular TEAE | “49 (71.0%)” | “8 (22.9%)” |
| Serious ocular TEAE | “0 (0.0%)” | “0 (0.0%)” |
| Ocular TEAE resulting in study-drug discontinuation | “4 (5.8%)” | “0 (0.0%)” |
| Ocular TEAE resulting in study discontinuation | “2 (2.9%)” | “0 (0.0%)” |

Source: [Belite Bio company presentation (2026)](https://investors.belitebio.com/static-files/837a64fe-a778-4209-9239-313d77a3aa0f)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

DRAGON enrolled 104 participants aged 12–20 years with defined atrophic lesions and visual acuity of 20/200 or better. Its modified full analysis set included 96 participants, rather than all randomized participants. The primary outcome was anatomical lesion growth; minimal visual-acuity change in both groups limits conclusions about functional benefit during the 24-month treatment period. These eligibility restrictions also limit direct applicability to younger children and participants outside the studied lesion-size and visual-acuity ranges.

Source: [Belite Bio first quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-first-quarter-2026-financial/); [Edwards et al. (2026)](https://onlinelibrary.wiley.com/doi/10.1111/ceo.70050); [Belite Bio company presentation (2026)](https://investors.belitebio.com/static-files/837a64fe-a778-4209-9239-313d77a3aa0f); [Belite Bio DRAGON topline results announcement (2025)](https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite/)

<a id="heading-3.1.2"></a>

#### 3.1.2 DRAGON II

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Study objective

> “The purpose of this study is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease.”

Source: [Mayo Clinic](https://www.mayo.edu/research/clinical-trials/cls-20571936)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Trial locations

> “Japan, the U.S., and the United Kingdom.”

Source: [Belite Bio second quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-second-quarter-2026-financial)

<a id="topic-3.1.2.2-2"></a>

###### UK protocol: ethics opinion

| Field | Quoted record |
| --- | --- |
| Ethics opinion date | “14 Jun 2024” |
| Ethics committee | “Wales REC 3” |

Source: [UK Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/lbs-008-ct07/)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### DRAGON II phase 1b and phase 2/3 trials: randomization

> “randomized (1:1, active: placebo)”

Source: [Belite Bio second quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-second-quarter-2026-financial)

<a id="topic-3.1.2.3-2"></a>

###### DRAGON II phase 1b and phase 2/3 trials: study duration and visits

> “The total study duration from screening through to follow-up is 26 months, with participants returning to the study site every 3 months for check-ups.”

Source: [UK Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/lbs-008-ct07/)

<a id="topic-3.1.2.3-3"></a>

###### Design of the phase 1b and phase 2/3 components

| Component and feature | Quoted record |
| --- | --- |
| Phase 1b masking | “open-label” |
| Phase 2/3 masking | “double-masked” |
| Phase 2/3 treatment duration | “24-month” |

Source: [Belite Bio second quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-second-quarter-2026-financial)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### DRAGON II phase 1b and phase 2/3 trials: inclusion criterion

> “Subjects must have clinically diagnosed STGD1 with at least one mutation identified in the ABCA4 gene.”

Source: [Mayo Clinic](https://www.mayo.edu/research/clinical-trials/cls-20571936)

<a id="topic-3.1.2.4-2"></a>

###### DRAGON II phase 1b and phase 2/3 trials: age range

> “12 to 20 years old”

Source: [Belite Bio second quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-second-quarter-2026-financial)

<a id="topic-3.1.2.4-3"></a>

###### DRAGON II phase 1b and phase 2/3 trials: exclusion criterion

> “Any prior gene therapy.”

Source: [Mayo Clinic](https://www.mayo.edu/research/clinical-trials/cls-20571936)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

Additional sources: [ClinicalTrials.gov NCT06388083](https://clinicaltrials.gov/study/NCT06388083)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Atrophic Lesion Growth as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary efficacy outcome and safety assessments

> “growth rate of atrophic lesions; safety and tolerability will also be assessed.”

Source: [Belite Bio second quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-second-quarter-2026-financial)

<a id="topic-3.1.2.6.1-2"></a>

###### Trial-specific endpoint-validation analysis

No evidence found.

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### DRAGON II phase 1b and phase 2/3 trials: enrollment

> “Completed enrollment with 73 subjects, including 15 Japanese subjects for the Phase 2/3 trial in STGD1.”

Source: [Belite Bio second quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-second-quarter-2026-financial)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The available update establishes enrollment of 73 participants, including 15 Japanese participants, in the phase 2/3 component. The evidence collected here describes its design and eligibility rather than treatment-effect estimates or completed safety results. Its age range of 12–20 years and requirement for clinically diagnosed STGD1 with an identified ABCA4 mutation constrain the population to which future findings can directly apply.

Source: [Belite Bio second quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-second-quarter-2026-financial); [Mayo Clinic](https://www.mayo.edu/research/clinical-trials/cls-20571936); [UK Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/lbs-008-ct07/)

<a id="heading-3.1.3"></a>

#### 3.1.3 LBS-008-CT02

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

Additional sources: [ClinicalTrials.gov NCT05266014](https://clinicaltrials.gov/study/NCT05266014)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

Additional sources: [ClinicalTrials.gov NCT05266014](https://clinicaltrials.gov/study/NCT05266014)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Phase 1b/2 dose-finding and two-year extension: design

> “open-label”

Source: [Belite Bio Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Phase 1b/2: adolescent age range

> “12-18 years”

Source: [ARVO Annual Meeting (2023)](https://investors.belitebio.com/static-files/a5527853-be5e-49c4-a007-c84e2850e85a)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Phase 1b/2: oral regimen

> “Tinlarebant (5 mg/day, p.o.)”

Source: [ARVO Annual Meeting (2023)](https://investors.belitebio.com/static-files/a5527853-be5e-49c4-a007-c84e2850e85a)

Additional sources: [Grigg et al. (2022)](https://iovs.arvojournals.org/article.aspx?articleid=2781626)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Systemic and Ocular Safety and Tolerability as the Primary Endpoint

Not applicable.

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Phase 1b/2 dose-finding and two-year extension: enrollment

> “13 adolescent STGD1 patients enrolled”

Source: [Belite Bio (2024)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-presents-additional-analysis-phase-2-study/)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### External natural-history comparison population

> “ProgStar participants possessing similar baseline characteristics (aged ≤18 years)”

Source: [Belite Bio (2023)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-presents-results-24-month-phase-2-study-tinlarebant)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Phase 1b/2 dose-finding and two-year extension: adverse-event withdrawals

> “no withdrawals due to adverse events”

Source: [Belite Bio (2023)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-presents-results-24-month-phase-2-study-tinlarebant)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Baseline genotype severity

> “Eleven of these subjects (85%) harbored severe pathogenic/likely pathogenic ABCA4 variants.”

Source: [Belite Bio (2024)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-presents-additional-analysis-phase-2-study/)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Phase 1b/2 dose-finding and two-year extension: 24-month results

> “42% of Tinlarebant-treated subjects (5 out of 12) did not develop atrophic retinal lesions during the 24-month treatment period”

Source: [Belite Bio (2023)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-presents-results-24-month-phase-2-study-tinlarebant)

<a id="topic-3.1.3.8.3-2"></a>

###### Phase 1b/2 dose-finding and two-year extension: additional analysis

> “In 6 subjects with prior bilateral BCVA loss (mean ~10 letters/year), mean BCVA loss over 24 months was 1.9 letters/year”

Source: [Belite Bio (2024)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-presents-additional-analysis-phase-2-study/)

Additional sources: [Grigg et al. (2023)](https://iovs.arvojournals.org/article.aspx?articleid=2787663)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Phase 1b/2 study: 18-month report

> “Tinlarebant is Safe and Well-Tolerated During 18 Months of Treatment”
> “All treatment-related AEs were mild in severity.”

Source: [ARVO Annual Meeting (2023)](https://investors.belitebio.com/static-files/a5527853-be5e-49c4-a007-c84e2850e85a)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The supporting study was open-label and enrolled 13 participants. Its 24-month lesion result was reported for 12 participants, and the visual-acuity analysis concerned a subgroup of 6 with prior bilateral visual loss. The natural-history comparison used selected ProgStar participants rather than a concurrently randomized placebo group. These design features and small denominators limit causal interpretation of lesion and visual-acuity findings. The reported genotype distribution, with severe pathogenic or likely pathogenic ABCA4 variants in 11 participants (85%), further describes the selected study population.

Source: [Belite Bio Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm); [Belite Bio (2024)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-presents-additional-analysis-phase-2-study/); [Belite Bio (2023)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-presents-results-24-month-phase-2-study-tinlarebant)

<a id="heading-3.1.4"></a>

#### 3.1.4 LBS-008-CT09

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Study objective

> “evaluate the effect of food and drug-drug interaction with tinlarebant.”

Source: [ANZCTR ACTRN12624000031561](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12624000031561)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Recruitment location and actual study dates

| Field | Quoted record |
| --- | --- |
| Site | “CMAX Clinical Research Pty Ltd - Adelaide” |
| First participant enrollment | “7/01/2024” |
| Last participant enrollment | “31/05/2024” |
| Last data collection | “5/07/2024” |

Source: [ANZCTR ACTRN12624000031561](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12624000031561)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Published study design

> “randomized, open-label, two-period, interaction study”

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="topic-3.1.4.3-2"></a>

###### Registry: overall allocation

> “Non-randomised trial”

Source: [ANZCTR ACTRN12624000031561](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12624000031561)

<a id="topic-3.1.4.3-3"></a>

###### Registry: food-effect treatment sequences

> “will be randomized into two treatment sequences:”

Source: [ANZCTR ACTRN12624000031561](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12624000031561)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Study population

> “healthy adults”

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="topic-3.1.4.4-2"></a>

###### Registered age limits

| Criterion | Quoted record |
| --- | --- |
| Minimum age | “18 Years” |
| Maximum age | “65 Years” |

Source: [ANZCTR ACTRN12624000031561](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12624000031561)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Tinlarebant dose

> “5 mg single dose”

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="topic-3.1.4.5-2"></a>

###### Perpetrator-drug regimens

| Drug | Quoted regimen |
| --- | --- |
| Omeprazole | “40 mg QD” |
| Itraconazole | “200 mg BD” |
| Rifampin | “600 mg QD” |

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Cmax and AUCinf as the Primary Pharmacokinetic Endpoints

Not applicable.

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned and enrolled participants

| Population | Quoted record |
| --- | --- |
| Target enrollment | “48” |
| Final enrollment | “49” |

Source: [ANZCTR ACTRN12624000031561](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12624000031561)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Exposure comparison method

> “geometric least squares (GLS) mean Cmax and AUCinf ratios”

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="topic-3.1.4.7.2-2"></a>

###### Analysis-set membership and exclusions

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Drug-interaction pharmacokinetic results

| Coadministration | “Cmax ratio” | “AUCinf ratio” |
| ---------------- | -----------: | -------------: |
| “omeprazole”     |       “1.16” |         “1.03” |
| “itraconazole”   |       “1.29” |         “2.42” |
| “Rifampin”       |       “0.53” |         “0.19” |

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="topic-3.1.4.8.3-2"></a>

###### Food-effect pharmacokinetic results

> “Cmax and AUCinf ratios”
> “1.08–1.22”

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Safety finding

> “No unexpected safety signals occurred”

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

This pharmacokinetic study enrolled 49 healthy adult participants and evaluated single-dose tinlarebant exposure with selected interacting drugs or food. Its exposure ratios do not establish long-term clinical efficacy in Stargardt disease. The registry records a non-randomized trial overall, whereas the publication describes a randomized, open-label, two-period interaction study; the registry’s food-effect component specifies randomized fed/fasted sequences. These descriptions should not be interpreted as a randomized comparison of all perpetrator-drug groups.

Source: [ANZCTR ACTRN12624000031561](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12624000031561); [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

## Related pages
- [Tinlarebant (LBS-008): Stargardt disease type 1](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Terms and abbreviations](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/terms-and-abbreviations.md)
- [Tinlarebant (LBS-008): Stargardt disease type 1](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/executive-summary.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Product information and disease description](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/product-information-and-disease-description.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Economic information and modeling report](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/economics) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/economics.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: References](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/references) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/references.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: prevalence by geography](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/prevalence) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/prevalence.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/cost-effectiveness-analyses.md)
